VERACYTE, INC. — Director's Dealing 2020

Dec 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERACYTE, INC. (VCYT)
CIK: 0001384101
Period of Report: 2020-12-02

Reporting Person: Kennedy Giulia C (Chief Scientific & Med Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-02	Common Stock	F	540	$55.08	Disposed	78859	Direct
2020-12-04	Common Stock	M	5312	$9.05	Acquired	84171	Direct
2020-12-04	Common Stock	M	4406	$5.98	Acquired	88577	Direct
2020-12-04	Common Stock	M	3750	$20.21	Acquired	92327	Direct
2020-12-04	Common Stock	S	3642	$55.777	Disposed	88685	Direct
2020-12-04	Common Stock	S	4279	$56.8555	Disposed	84406	Direct
2020-12-04	Common Stock	S	6094	$57.5536	Disposed	78312	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-04	Stock Option (right to buy)	$9.05	M	5312	Disposed	2027-03-02	Common Stock (5312)	Direct
2020-12-04	Stock Option (right to buy)	$5.98	M	4406	Disposed	2028-03-01	Common Stock (4406)	Direct
2020-12-04	Stock Option (right to buy)	$20.21	M	3750	Disposed	2029-02-27	Common Stock (3750)	Direct

Footnotes

F1: The reporting person is reporting the withholding of 292 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587 and 500 Restricted Stock Units, respectively granted on March 2, 2018 and February 28, 2019, respectively, and does not represent a sale by the reporting person.

F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020.

F3: Represents weighted average sales price. Sale prices for the transactions range from $55.27 to $56.13. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.

F4: Represents weighted average sales price. Sale prices for the transactions range from $56.28 to $57.11. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.

F5: Represents weighted average sales price. Sale prices for the transactions range from $57.31 to $57.90. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.

F6: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous
service thereafter.

F7: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous
service thereafter.

F8: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous
service thereafter.